Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lifirafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | RAF1 | P04049 | 17/20 | 1.00 |
| ▸ | ARAF | P10398 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lifirafenib SCHEMBL29464034 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085317 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL29749194 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085288 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL20133921 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085289 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL24916576 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL15085287 | 1.00 | BRAF (1.00) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL29750805 | 0.94 | BRAF (0.89) | BRAFRAF1ARAF | |
| Lifirafenib SCHEMBL29750807 | 0.94 | BRAF (0.89) | BRAFRAF1ARAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119559-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BeiGene, Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| US-20180127412-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BEONE MEDICINES I GMBH (CH) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127412-A1 | MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885ARAF 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.